Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline

Noam Yarom, Charles L. Shapiro, Douglas E. Peterson, Catherine H. Van Poznak, Kari Bohlke*, Salvatore L. Ruggiero, Cesar A. Migliorati, Aliya Khan, Archie Morrison, Holly Anderson, Barbara A. Murphy, Devena Alston-Johnson, Rui Amaral Mendes, Beth Michelle Beadle, Siri Beier Jensen, Deborah P. Saunders

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE To provide guidance regarding best practices in the prevention and management of medicationrelated osteonecrosis of the jaw (MRONJ) in patients with cancer. METHODS Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. PubMed and EMBASE were searched for studies of the prevention and management of MRONJ related to bone-modifying agents (BMAs) for oncologic indications published between January 2009 and December 2017. Results from an earlier systematic review (2003 to 2008) were also included. RESULTS The systematic review identified 132 publications, only 10 of which were randomized controlled trials. Recommendations underwent two rounds of consensus voting. RECOMMENDATIONS Currently, MRONJ is defined by (1) current or previous treatment with a BMA or angiogenic inhibitor, (2) exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region and that has persisted for longer than 8 weeks, and (3) no history of radiation therapy to the jaws or metastatic disease to the jaws. In patients who initiate a BMA, preventive care includes comprehensive dental assessments, discussion of modifiable risk factors, and avoidance of elective dentoalveolar surgery (ie, surgery that involves the teeth or contiguous alveolar bone) during BMA treatment. It remains uncertain whether BMAs should be discontinued before dentoalveolar surgery. Staging of MRONJ should be performed by a clinician with experience in the management of MRONJ. Conservative measures comprise the initial approach to MRONJ treatment. Ongoing collaboration among the dentist, dental specialist, and oncologist is essential to optimal patient care.

Original languageEnglish
Pages (from-to)2270-2290
Number of pages21
JournalJournal of Clinical Oncology
Volume37
Issue number25
DOIs
StatePublished - 1 Sep 2019

Fingerprint

Dive into the research topics of 'Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline'. Together they form a unique fingerprint.

Cite this